Helium One Global Ltd Announces Company Receives Offer of Mining Licence
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019.
Company Receives Offer of Mining Licence for Southern Rukwa Helium Project, Tanzania
LONDON / ACCESS Newswire / March 3, 2025 / Helium One Global (AIM:HE1), the primary helium explorer in Tanzania with a 50% working interest in the Galactica-Pegasus helium development project in Colorado, USA, is pleased to provide the following update on its southern Rukwa Helium Project in Tanzania.
Highlights
The Company has received an offer letter from the Mining Commission ('MC') in Tanzania for the grant of a Mining Licence ('ML') for the southern Rukwa Helium Project
The potential ML will be for an area of approximately 480km2 and will cover all of the southern Rukwa Helium Project in the Momba, Sumbawanga Districts in the southern Rukwa Basin and is consistent with the area that was applied for under the application
The offer of the ML follows approval by the Ministry of Minerals ('MoM') who have given the MC permission to grant a larger than standard ML that will enable the southern Rukwa Helium Project to be developed to its full potential
Offer letter and terms are currently being reviewed by the Company
Lorna Blaisse, Chief Executive Officer, commented:
'As we continue to drive forward, this achievement for the Company marks a milestone in our progress as the primary helium company in Tanzania.
This historical moment, for both the Company and for Tanzania, is the first ML to be offered for helium in Tanzania and also the first of such a significant size. I would like to express my appreciation to the Ministry of Minerals and the Mining Commission for their support of this application and project, and for entrusting the Company in paving the way for this flagship commodity sector in-country. I would like to thank the Helium One team who have worked so hard on this and to all our shareholders for their continued support.'
Details
The offer letter of the ML is an achievement for the Company, following the discovery at Itumbula West-1 last year. The ML application, which was submitted in September 2024, was accompanied by a feasibility study which outlines the potential of the helium resource in southern Rukwa.
Following approval from the MoM, the MC were able to allow the full 480km2 which was applied for, and which is significantly larger than a standard ML area for conventional mining practices. The MoM and MC recognise that the helium potential in southern Rukwa is geologically unique given the gas in solution play, and that the Company has identified extensive faulting mechanisms and fracture networks and by including these in the ML area, it provides the Company with the best opportunity to fully leverage the helium potential.
The offer letter and terms are now under detailed review by the Company and further announcements will be made in due course.
Contact
Notes to Editors
Helium One Global, the AIM-listed Tanzanian explorer, holds prospecting licences across two distinct project areas, with the potential to become a strategic player in resolving a supply-constrained helium market.
The southern Rukwa and Eyasi projects are located within rift basins on the margin of the Tanzanian Craton in the north and southwest of the country. These assets lie near surface seeps with helium concentrations ranging up to 10.4% helium by volume. All Helium One's licences are held on a 100% equity basis.
The Company's flagship southern Rukwa Helium Project is located within the southern Rukwa Rift Basin covering 1,664km2 in south-west Tanzania. This project is considered to be entering an appraisal stage following the success of the 2023/24 exploration drilling campaign, which proved a helium discovery at Itumbula West-1 and, following an extended well test, successfully flowed 5.5% helium continually to surface in Q3 2024.
Following the success of the extended well test, the Company has now flowed significant quantities of helium to surface and has filed a Mining Licence application with the Mining Commission of the Tanzanian Government.
The Company also owns a 50% working interest in the Galactica-Pegasus helium development project in Las Animas County, Colorado, USA. This project is operated by Blue Star Helium Ltd (ASX: BNL).
Helium One is listed on the AIM market of the London Stock Exchange with the ticker of HE1 and on the OTCQB in the United States with the ticker HLOGF.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Tikehau Capital: Disclosure of Shares Repurchases from 06 June 2025 to 12 June 2025
PARIS--(BUSINESS WIRE)--Regulatory News: In accordance with Article 5 of EU Regulation n° 596/2014 (Market Abuse Regulation), detailed information is available on the website of Tikehau Capital (Paris:TKO): Name of the issuer Issuer Identity Code (LEI) Trading Day ISIN Aggregated volume per day (number of shares) Weighted average price per day Market (MIC Code) TIKEHAU CAPITAL 969500BY8TEU16U3SJ94 06/06/2025 FR0013230612 1,016 19.1754 XPAR TIKEHAU CAPITAL 969500BY8TEU16U3SJ94 09/06/2025 FR0013230612 463 19.1254 XPAR TIKEHAU CAPITAL 969500BY8TEU16U3SJ94 10/06/2025 FR0013230612 1,071 19.0114 XPAR TIKEHAU CAPITAL 969500BY8TEU16U3SJ94 11/06/2025 FR0013230612 892 19.0490 XPAR TIKEHAU CAPITAL 969500BY8TEU16U3SJ94 12/06/2025 FR0013230612 1,086 18.8606 XPAR TOTAL 4,528 19.0311 Expand
Yahoo
3 hours ago
- Yahoo
Resolutions of the shareholders of Hepsor AS – adoption of resolutions of the general meeting without calling a meeting
The management board of Hepsor AS, registry code 12099216 (hereinafter the Company) published on 5 June 2025 pursuant to § 2991 subsections 1, 2 and 3 of the Commercial Code the draft resolutions for the adoption of shareholders' resolutions without calling a meeting. The list of shareholders entitled to vote was determined as at seven days before the voting term, i.e. on 5 June 2025 at the end of the business day of the settlement system of Nasdaq CSD Estonia. The Company has a total of 9,142 shareholders, who own a total of 3,854,701 shares. The deadline for shareholders to submit their positions was on 12 June 2025 at 23:59 Estonian time. Six shareholders of the Company submitted their vote, whose shares represent in total 2,978,700 votes, that forms 77.27% of all votes determined by shares. The shareholders of the Company adopted the following resolutions Approval of the acquisition of a minority shareholding in Hepsor Latvia OÜ To approve the transaction whereby the Company acquires the share of Hepsor Latvia OÜ from Hugomon OÜ, which represents 20% of the share capital of Hepsor Latvia OÜ, on the following main terms and conditions: The Company will pay 20,000 euros in cash to Hugomon OÜ for the share of Hepsor Latvia OÜ and will issue 57,821 shares of the Company to Hugomon OÜ, whereas upon the issue of the Company's shares, Hugomon OÜ will pay for the shares with the share of Hepsor Latvia OÜ as a non-monetary contribution; By amending the articles of association, the Supervisory Board of the Company is given the right to increase the share capital of the Company and to issue new shares to Hugomon OÜ; The subscription right for the new shares will be given to Hugomon OÜ and the pre-emptive subscription right of the existing shareholders will be excluded. 2,978,700 votes were in favour of the resolution i.e. 77.27% of all votes represented by shares, 876,001 votes opposed or did not vote i.e. 22.73% of all votes represented by shares. Thus, the resolution has been adopted in the wording above. Amendment of the articles of association To amend the articles of association of the Company and adopt the articles of association of the Company in the new wording, in the form presented to the general meeting. 2,978,700 votes were in favour of the resolution i.e. 77.27% of all votes represented by shares, 876,001 votes opposed or did not vote i.e. 22.73% of all votes represented by shares. Thus, the resolution has been adopted in the wording above. Exclusion of pre-emptive subscription rights To exclude the Company's shareholders' pre-emptive subscription rights upon the increase of the share capital and the issuance of 57,821 new shares in connection with the acquisition of the share of Hepsor Latvia OÜ from Hugomon OÜ. 2,978,700 votes were in favour of the resolution i.e. 77.27% of all votes represented by shares, 876,001 votes opposed or did not vote i.e. 22.73% of all votes represented by shares. Thus, the resolution has been adopted in the wording above. Additional information: Henri LaksMember of the management boardTel: +372 5693 9114E-mail: henri@ Hepsor AS ( is a developer of residential and commercial real estate. The Group operates in Estonia, Latvia and Canada. During our fourteen years of operation, we have created 2,076 homes and nearly 36,300 m2 of commercial space. As the first developer in the Baltic countries, Hepsor has implemented several innovative engineering and technical solutions that make the buildings built by the company more energy-efficient and thus more environmentally friendly. The company's portfolio includes a total of 25 development projects with a total area of 172,800 m2.
Business Insider
4 hours ago
- Business Insider
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) ('CERo'), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has issued additional shares of its Series D Preferred Stock to certain institutional investors (the 'Investors') pursuant to the securities purchase agreement previously entered into by and between the Company and such Investors on April 22, 2025 with respect to the issuance of shares of Series D Preferred Stock for an aggregate purchase price of up to $8 million, including $5 million previously issued in April 2025 and up to $3 million issuable at the option of the Investors. The shares of Series D Preferred Stock are convertible into shares of the Company's common stock. 'We welcome this vote of confidence and the continued support of our investors as we continue to show progress along our clinical timeline. The completion of our first-in-human dosing represents a significant clinical development milestone in AML for CER-1236, a novel autologous CAR-T therapeutic candidate targeting TIM 4L, and we will continue to communicate results as the data matures,' said Chris Ehrlich, Chief Executive Officer. The gross proceeds to CERo from today's closing are expected to be approximately $750,000, with up to $2.25 million of cash that may be funded at one or more additional closings, at the election of the Investors. CERo intends to use the net proceeds from the offering to take advantage of the two recent FDA IND allowances in liquid and solid tumors and complete the previously announced site activation at MDACC, as well as bring other sites online quickly. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. In April 2025, CERo initiated clinical trials for its lead product candidate, CER-1236,for hematological malignancies. Forward-Looking Statements This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo's management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 15, 2025, and the documents incorporated by reference therein. The risks described in CERo's filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
